Clinical trial results published in a peer-reviewed journal

Eli Lilly Seeks FDA Approval for Zepbound to Treat Sleep Apnea, Resolving Symptoms in Up to 52% of Patients

Jun 21, 2024, 08:14 PM

Eli Lilly has formally requested FDA approval to expand the use of its weight-loss drug Zepbound to treat obstructive sleep apnea (OSA). The company announced that Zepbound, also known as tirzepatide, has shown significant efficacy in resolving moderate to severe OSA in up to 52% of patients in two late-stage clinical trials. In addition to improving sleep apnea symptoms, the drug also improved body weight, the apnea-hypopnea index, hypoxic burden, hsCRP concentration, and systolic blood pressure. Zepbound helped at least 43% of patients with OSA and obesity resolve symptoms. Up to 51.5% of participants met the criteria for disease resolution. Eli Lilly anticipates a decision from the FDA by the end of the year.